bevacizumab,tucatinib,trifluridine tipiracil,trastuzumab
roche,otsuka,seagen,taiho pharma
[]
day 3 #gi23 highlights #communityoncology 1. #mountaineer: tucat+trast approved crc 2. #sunlight: tas102+bev confirmed late option crc 3. #e2211: cape+tem in pnet manuscript 4. #ctdna kinetics crc 5. tnt state in rectalca #onced #meded #gism #medtwitter
Practice changing #Oncology news from #CommunityOncologists perspective w/ Rohit Gosain @UPMCHillmanCC & Rahul Gosain @WilmotCancer. Views are our own.